Evidence map›Paper›PMID 42550221›Full record

ArticleActa diabetologica2026

Methodological considerations in the UK Biobank diabetes‑tinnitus study.

Axmedova Maxbuba, Abdurazakova Dilbar, Dilbar Urazbaeva, Sanjar Zaripov, Arman Abroumand Gholami

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Acta diabetologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Axmedova MaxbubaDepartment of Hospital Therapy and Endocrinology, Samarkand state Medical University, Samarkand, Uzbekistan.
Abdurazakova DilbarDepartment of Hospital Therapy and Endocrinology, Andijan State Medical Institute, Andijan, Uzbekistan.
Dilbar UrazbaevaDepartment of Psychology and Medicine, Mamun university, Urgench, Uzbekistan.
Sanjar ZaripovDepartment of Internal medicine in family medicine, Tashkent State Medical University, Tashkent, Uzbekistan.
Arman Abroumand GholamiNervous System Stem Cell Research Center, Semnan University of Medical Sciences, Semnan, Iran. aroma3162@gmail.com.ORCID http://orcid.org/0009-0002-8942-7918

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tinnitus is a common and often debilitating condition that substantially affects quality of life. While diabetes has been suggested as a potential risk factor, the relationship remains poorly understood, particularly in large population-based settings where classification of diabetes type often relies on algorithms rather than confirmatory biomarkers. The recent UK Biobank study by Ji and colleagues addresses this gap by reporting that type 2 diabetes is associated with higher tinnitus prevalence. While the study benefits from a large sample and systematic examination of diabetes-related factors, two methodological concerns warrant consideration before the findings are interpreted as robust evidence. First, diabetes type was determined using algorithmic classification without confirmatory biomarkers such as autoantibodies or C-peptide. Second, the analytical strategy treated age as a simple covariate, implicitly assuming that the diabetes-tinnitus association remains constant across the entire 40-70 year age range. While the study offers valuable hypothesis-generating data, these methodological considerations suggest that the reported associations should be interpreted cautiously until confirmed by biomarker-validated phenotyping and more flexible analytical approaches that account for age-related heterogeneity.

Indexed as

Diabetes mellitusMethodological biasTinnitusUK Biobank

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.